2 hours ago
Outlook Therapeutics (OTLK) Stock Soars 12% Following Lytenava FDA Approval
Outlook Therapeutics (OTLK) stock surges after FDA approves Lytenava for wet AMD treatment. Analysts project potential 290% upside with Buy ratings.
The post Outlook Therapeutics (OTLK) Stock Soars 12% Following Lytenava FDA Approval appeared first on Blockonomi.
Source: Blockonomi →Related News
- 48 minutes ago
Strategy Inc. (MSTR) Stock Gains as Company Boosts Cash Reserves by $525M and Bu...
- 56 minutes ago
Semiconductor Stocks Plunge as China’s Chipmaking Breakthrough Shakes Markets
- 1 hour ago
ASML (ASML) Stock Plunges 7% as China Announces Domestic DUV Lithography Product...
- 1 hour ago
Seagate (STX) Stock Rises Ahead of Tuesday’s Earnings Report: Is Now the Time to...
- 1 hour ago
Bitmine (BMNR) Stock Surges 5% Following Strategic Ethereum Acquisition and Shar...